Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC statin favored

This article was originally published in The Tan Sheet

Executive Summary

The National Consumers League says a majority of U.S. consumers with at-risk cholesterol levels (82 percent) would be more likely to consider taking an OTC statin drug than an Rx product. Participants in an NCL survey say an OTC product is more appealing, largely because of convenience factors. They also consider OTC statins safer, more natural, more suitable for people taking charge of their health and less likely to cause side effects than Rx statins. The survey found consumers are three times more likely to seek additional information about an OTC statin than an Rx product (79 percent versus 21 percent). FDA advisory committees on Dec. 13 recommended against approving Merck's third OTC switch application for lovastatin 20 mg (1"The Tan Sheet" Dec. 17, 2007, p. 3)...

You may also be interested in...

FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins

More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin

ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN

Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.

ESMO: Evidence Piles Up For AZ’s Tagrisso With ADAURA CNS Data

A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts